JP2013531041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531041A5 JP2013531041A5 JP2013519806A JP2013519806A JP2013531041A5 JP 2013531041 A5 JP2013531041 A5 JP 2013531041A5 JP 2013519806 A JP2013519806 A JP 2013519806A JP 2013519806 A JP2013519806 A JP 2013519806A JP 2013531041 A5 JP2013531041 A5 JP 2013531041A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- sustained release
- sialic acid
- release
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013268 sustained release Methods 0.000 claims description 57
- 239000012730 sustained-release form Substances 0.000 claims description 57
- 238000009472 formulation Methods 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 41
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 33
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 33
- 239000003405 delayed action preparation Substances 0.000 claims description 31
- 229920000642 polymer Polymers 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 13
- 208000013135 GNE myopathy Diseases 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000021642 Muscular disease Diseases 0.000 claims description 7
- 201000009623 Myopathy Diseases 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000416 hydrocolloid Substances 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 229960003943 hypromellose Drugs 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 2
- 238000009505 enteric coating Methods 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 14
- 239000003814 drug Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 241000202785 Calyptronoma Species 0.000 description 2
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 201000009338 distal myopathy Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36399510P | 2010-07-13 | 2010-07-13 | |
| US61/363,995 | 2010-07-13 | ||
| PCT/US2011/043910 WO2012009474A1 (en) | 2010-07-13 | 2011-07-13 | Method and formulations for treating sialic acid deficiencies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531041A JP2013531041A (ja) | 2013-08-01 |
| JP2013531041A5 true JP2013531041A5 (enExample) | 2014-05-15 |
| JP5777712B2 JP5777712B2 (ja) | 2015-09-09 |
Family
ID=45469794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519806A Active JP5777712B2 (ja) | 2010-07-13 | 2011-07-13 | シアル酸欠乏症を治療するための方法および製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9511015B2 (enExample) |
| EP (1) | EP2593109A4 (enExample) |
| JP (1) | JP5777712B2 (enExample) |
| KR (1) | KR20140003380A (enExample) |
| CN (2) | CN103370069A (enExample) |
| AU (1) | AU2011279158B2 (enExample) |
| BR (1) | BR112013000776A2 (enExample) |
| CA (1) | CA2805222A1 (enExample) |
| IL (1) | IL224203B (enExample) |
| WO (1) | WO2012009474A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| BR112013000776A2 (pt) | 2010-07-13 | 2016-05-24 | Ultragenyx Pharmaceutical Inc | método e formulação para tratamento de deficiência de ácido siálico |
| WO2013063149A1 (en) | 2011-10-24 | 2013-05-02 | Ultragenyx Pharmaceutical, Inc. | Sialic acid analogs |
| CN104271125A (zh) * | 2012-01-18 | 2015-01-07 | 奥特吉尼克斯制药公司 | 用于治疗唾液酸缺乏的方法和制剂 |
| WO2014031837A1 (en) * | 2012-08-22 | 2014-02-27 | The Regents Of The University Of California | Compositions and methods for enhancing sialic acid levels in tissue |
| US20170306046A1 (en) | 2014-11-12 | 2017-10-26 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2017048817A1 (en) | 2015-09-14 | 2017-03-23 | Ultragenyx Pharmaceutical Inc. | Crystal forms of sialic acid or salt or solvate thereof |
| CN108463248B (zh) | 2015-11-12 | 2022-10-21 | 西雅图基因公司 | 聚糖相互作用化合物及使用方法 |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
| EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE |
| WO2019089550A1 (en) * | 2017-10-31 | 2019-05-09 | Once Labs Inc. | Automated feedback-driven prognosis system and method |
| EP3486326A1 (en) | 2017-11-21 | 2019-05-22 | Jennewein Biotechnologie GmbH | Method for the purification of n-acetylneuraminic acid from a fermentation broth |
| US20200371110A1 (en) * | 2018-01-12 | 2020-11-26 | The Wistar Institute Of Anatomy And Biology | Methods for identifying and treating hiv persistence |
| CN110548012B (zh) * | 2019-08-27 | 2022-05-13 | 嘉必优生物技术（武汉）股份有限公司 | 一种唾液酸片剂及其制备方法 |
| TW202513040A (zh) * | 2023-09-01 | 2025-04-01 | 瑞士商赫孚孟拉羅股份公司 | 製備半固體組成物之新穎方法及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6168418A (ja) | 1984-09-11 | 1986-04-08 | Kanto Ishi Pharma Co Ltd | 去痰薬 |
| CA2215978A1 (en) | 1995-04-04 | 1996-10-10 | Wound Healing Of Oklahoma | Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| WO1999052931A1 (fr) | 1998-04-10 | 1999-10-21 | Mitsubishi Chemical Corporation | Dispersion solide contenant un derive d'acide sialique |
| BR0311978A (pt) * | 2002-06-21 | 2005-03-22 | Novo Nordisk Healthcare Ag | Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação |
| US7238677B2 (en) * | 2003-03-28 | 2007-07-03 | Kimberly-Clark Worldwide, Inc. | Prevention of urogenital infections |
| AU2004296404A1 (en) | 2003-12-09 | 2005-06-23 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
| KR101202607B1 (ko) * | 2005-03-03 | 2012-11-20 | 마나테크 인코포레이티드 | 영양 보조제의 조절된 방출을 위한 방법 및 조성물 |
| WO2007103286A2 (en) | 2006-03-02 | 2007-09-13 | Spherics, Inc. | Rate-controlled bioadhesive oral dosage formulations |
| US9744137B2 (en) | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| WO2008150477A2 (en) * | 2007-05-31 | 2008-12-11 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | N-acetyl mannosamine as a therapeutic agent |
| CA2698108A1 (en) | 2007-08-27 | 2009-03-12 | Massachusetts Institute Of Technology | Bi-functional polymer-attached inhibitors of influenza virus |
| WO2009137827A2 (en) | 2008-05-09 | 2009-11-12 | Tiara Pharmaceuticals, Inc. | Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation |
| KR101116864B1 (ko) | 2008-08-01 | 2012-02-29 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
| US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
| US20100160363A1 (en) | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| JP5626734B2 (ja) | 2009-05-15 | 2014-11-19 | 公益財団法人ヒューマンサイエンス振興財団 | Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物 |
| BR112013000776A2 (pt) | 2010-07-13 | 2016-05-24 | Ultragenyx Pharmaceutical Inc | método e formulação para tratamento de deficiência de ácido siálico |
| WO2013063149A1 (en) | 2011-10-24 | 2013-05-02 | Ultragenyx Pharmaceutical, Inc. | Sialic acid analogs |
| CN104271125A (zh) | 2012-01-18 | 2015-01-07 | 奥特吉尼克斯制药公司 | 用于治疗唾液酸缺乏的方法和制剂 |
-
2011
- 2011-07-13 BR BR112013000776A patent/BR112013000776A2/pt not_active IP Right Cessation
- 2011-07-13 CA CA2805222A patent/CA2805222A1/en not_active Abandoned
- 2011-07-13 WO PCT/US2011/043910 patent/WO2012009474A1/en not_active Ceased
- 2011-07-13 KR KR1020137003511A patent/KR20140003380A/ko not_active Ceased
- 2011-07-13 EP EP11807478.0A patent/EP2593109A4/en not_active Withdrawn
- 2011-07-13 AU AU2011279158A patent/AU2011279158B2/en not_active Ceased
- 2011-07-13 US US13/810,068 patent/US9511015B2/en active Active
- 2011-07-13 JP JP2013519806A patent/JP5777712B2/ja active Active
- 2011-07-13 CN CN2011800439776A patent/CN103370069A/zh active Pending
- 2011-07-13 CN CN201810170704.1A patent/CN108606956A/zh active Pending
-
2013
- 2013-01-13 IL IL224203A patent/IL224203B/en not_active IP Right Cessation
- 2013-01-18 US US13/745,106 patent/US9554987B2/en not_active Expired - Fee Related
-
2016
- 2016-10-26 US US15/334,885 patent/US20170136051A1/en not_active Abandoned
- 2016-12-19 US US15/383,682 patent/US20170157160A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5819329B2 (ja) | アルコール耐性腸溶性医薬組成物 | |
| JP2013545762A5 (enExample) | ||
| KR101317592B1 (ko) | 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제 | |
| JP2011098964A5 (enExample) | ||
| US9629808B2 (en) | Sustained-release solid preparation for oral use | |
| RU2744576C2 (ru) | Пероральные фармацевтические композиции месалазина | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| JP2014533656A5 (enExample) | ||
| EP2726064B1 (en) | Controlled release oral dosage form comprising oxycodone | |
| TW201334780A (zh) | 多西拉敏及吡哆醇及／或其代謝物或鹽之調配物 | |
| JP2021500377A (ja) | 遅延放出デフェリプロン錠剤及びその使用法 | |
| JP2021152050A (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| US20250235445A1 (en) | Novel pharmaceutical formulation | |
| HRP20241424T1 (hr) | Pripravak koji sadrži ramipril i indapamid | |
| JP5697668B2 (ja) | 口腔内崩壊錠剤 | |
| US20110300209A1 (en) | Modified release solid pharmaceutical compositions of trimetazidine and process thereof | |
| KR20180083239A (ko) | 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물 | |
| RU2738114C2 (ru) | Пероральные фармацевтические композиции никотинамида | |
| JP2015504094A5 (enExample) | ||
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| KR20100124860A (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| JP6854162B2 (ja) | 錠剤 | |
| CA2645260A1 (en) | Renin inhibitors for the treatment of hypertension | |
| JP2016504390A5 (enExample) | ||
| JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 |